Details for New Drug Application (NDA): 210838
✉ Email this page to a colleague
NDA 210838 describes NIFEDIPINE, which is a drug marketed by Acella, Actavis Elizabeth, Chase Labs Nj, Heritage Pharma, Teva, Velzen Pharma Pvt, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Aurobindo Pharma Usa, Elite Pharm Solution, Endo Operations, Martec Usa Llc, Norvium Bioscience, Novast Labs, Osmotica Pharm Us, Rising, Spil, Swiss Pharm, Twi Pharms, Valeant Pharms North, and Zydus Pharms, and is included in thirty NDAs. It is available from thirty-six suppliers. Additional details are available on the NIFEDIPINE profile page.
The generic ingredient in NIFEDIPINE is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
The generic ingredient in NIFEDIPINE is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
Summary for 210838
| Tradename: | NIFEDIPINE |
| Applicant: | Spil |
| Ingredient: | nifedipine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210838
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 30MG | ||||
| Approval Date: | Apr 16, 2019 | TE: | AB2 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 60MG | ||||
| Approval Date: | Apr 16, 2019 | TE: | AB2 | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 90MG | ||||
| Approval Date: | Apr 16, 2019 | TE: | AB2 | RLD: | No | ||||
Complete Access Available with Subscription
